Apollomics Inc (APLM)

Currency in USD
20.3000
+0.0700(+0.35%)
Closed·
20.30000.0000(0.00%)
·
APLM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
20.010020.6600
52 wk Range
3.659042.1200
Key Statistics
Prev. Close
20.23
Open
20.66
Day's Range
20.01-20.66
52 wk Range
3.659-42.12
Volume
6.55K
Average Volume (3m)
23.4K
1-Year Change
180%
Book Value / Share
-3.99
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
APLM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Apollomics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Apollomics Company Profile

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways that is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its immuno-oncology product candidates comprise APL-501, APL-502, and APL-801. The company was founded in 2015 and is based in Foster City, California.

Compare APLM to Peers and Sector

Metrics to compare
APLM
Peers
Sector
Relationship
P/E Ratio
−1.4x−2.4x−0.5x
PEG Ratio
−0.03−0.100.00
Price/Book
−9.9x1.6x2.6x
Price / LTM Sales
6.3x91.9x3.3x
Upside (Analyst Target)
-396.0%45.6%
Fair Value Upside
Unlock16.5%4.9%Unlock
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Dec 22, 2025
EPS / Forecast
-11.37 / --
Revenue / Forecast
8.50M / --
EPS Revisions
Last 90 days

People Also Watch

15.02
KELYB
-0.07%
1.840
FEAM
-10.68%
11.980
KG
+0.59%
1.78
FATN
-0.56%

FAQ

What Is the Apollomics (APLM) Share Price Today?

The live Apollomics share price today is 20.3000

What Stock Exchange Does Apollomics (APLM) Trade On?

Apollomics is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Apollomics?

The stock symbol (also called a 'ticker') for Apollomics is "APLM."

What Is the Current Apollomics Market Cap?

As of today, Apollomics market capitalisation is 43.4200M.

What Is Apollomics's (APLM) Earnings Per Share (TTM)?

The Apollomics EPS is currently -28.2963 (Trailing Twelve Months).

Is APLM a Buy or Sell From a Technical Analyst Perspective?

Based on today's Apollomics moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Apollomics Stock Split?

Apollomics has split 1 times. (See the APLM stock split history page for full effective split date and price information.)

How Many Employees Does Apollomics Have?

Apollomics has 13 employees.

What is the current trading status of Apollomics (APLM)?

As of 19/02/2026, Apollomics (APLM) is trading at a price of 20.3000, with a previous close of 20.2300. The stock has fluctuated within a day range of 20.0100 to 20.6600, while its 52-week range spans from 3.6590 to 42.1200.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.